MRK vs QCOM: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-16.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction Grade B
VS
QUALCOMM Incorporated · Technology
$134.47
+77.7% upside to fair value
Med Conviction Grade B
QuantHub Verdict
QCOM has more upside to fair value (+77.7%). MRK trades at a lower forward P/E (14.0x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric MRK QCOM
Current Price $121.42 $134.47
Fair Value Estimate $118.00 $239.00
Upside to Fair Value -2.9% +77.7%
Market Cap $300.2B $143.6B
Forward P/E 14.0x 26.8x
EV / EBITDA 11.8x
Price / Sales 4.1x 3.2x
Price / FCF 21.4x 11.1x
Revenue Growth YoY +1.3% +8.7%
Gross Margin 81.5% 55.1%
Operating Margin 41.2% 27.1%
Return on Equity 34.7% 21.6%
Dividend Yield 3.1%
FCF Yield 4.7% 9.0%
Analyst Consensus Buy Hold
Investment Thesis
MRK — Merck & Co., Inc.
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
QCOM — QUALCOMM Incorporated
Qualcomm Incorporated is a leading semiconductor company specializing in wireless chipsets and IP licensing, with dominant positions in 5G modems via QCT (87% of revenue) and steady QTL royalties. The business excels through a vast patent moat, diversification into automotive and IoT, and robust growth (revenue +13% YoY to $44B in FY2025), but faces risks from Apple modem shifts and China exposur…
Accumulation Zones
Metric MRK QCOM
Zone Low $88.00 $179.00
Zone High $100.00 $203.00
In Buy Zone? No Yes
← MRK Research    QCOM Research →    All Research